Search Results 51-60 of 21353 for anti-TNF drugs

  1. Etanercept-Ykro (Subcutaneous Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  2. Adalimumab-Bwwd (Subcutaneous Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  3. Adalimumab-Adbm (Subcutaneous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  4. Adalimumab-Fkjp (Subcutaneous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  5. Adalimumab-Aqvh (Subcutaneous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  6. Weekend Wellness: Ankylosing spondylitis symptom changes hard to predict - Mayo Clinic News Network

    When these symptoms are persistent, treatment usually involves medications known as TNF blockers. ... Examples of these medications include adalimumab, etanercept ...

  7. Etanercept-Szzs (Subcutaneous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  8. Rheumatoid Arthritis Clinical Trials - Mayo Clinic Research

    ... treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis ...

  9. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

    * Must have failed anti-TNF treatment for HS. * To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.

  10. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

    Anti-TNF Therapy. Inadequate primary non-response: Did not respond (as ... Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs). Prophylactic ...